Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors

NCT05985161 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05985161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05985161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2023
Completion date
August 1, 2029
Enrollment
45 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

malignant peripheral nerve sheath tumors, mpnst, nephroblastoma, rhabdoid tumor, solid tumor, wilms tumor, xpo1 gene mutation